These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 35466182)

  • 21. A review of thrombotic microangiopathies in multiple myeloma.
    Portuguese AJ; Gleber C; Passero FC; Lipe B
    Leuk Res; 2019 Oct; 85():106195. PubMed ID: 31404728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs).
    Williams LA; Marques MB;
    Am J Clin Pathol; 2016 Feb; 145(2):158-65. PubMed ID: 27124904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab.
    Raufi AG; Scott S; Darwish O; Harley K; Kahlon K; Desai S; Lu Y; Tran MH
    Hematol Rep; 2016 Sep; 8(3):6625. PubMed ID: 27781079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indicators Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies in a Canadian Apheresis Referral Center.
    Martin SD; McGinnis E; Smith TW
    Am J Clin Pathol; 2021 Nov; 156(6):1103-1112. PubMed ID: 34160013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management.
    Mazzierli T; Allegretta F; Maffini E; Allinovi M
    Front Pharmacol; 2022; 13():1088031. PubMed ID: 36699080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: A systematic review and meta-analysis.
    Paydary K; Banwell E; Tong J; Chen Y; Cuker A
    Transfusion; 2020 Sep; 60(9):2047-2057. PubMed ID: 32757237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study.
    Bendapudi PK; Hurwitz S; Fry A; Marques MB; Waldo SW; Li A; Sun L; Upadhyay V; Hamdan A; Brunner AM; Gansner JM; Viswanathan S; Kaufman RM; Uhl L; Stowell CP; Dzik WH; Makar RS
    Lancet Haematol; 2017 Apr; 4(4):e157-e164. PubMed ID: 28259520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombotic microangiopathies: a general approach to diagnosis and management.
    Arnold DM; Patriquin CJ; Nazy I
    CMAJ; 2017 Jan; 189(4):E153-E159. PubMed ID: 27754896
    [No Abstract]   [Full Text] [Related]  

  • 29. Proteasome inhibitor associated thrombotic microangiopathy.
    Yui JC; Van Keer J; Weiss BM; Waxman AJ; Palmer MB; D'Agati VD; Kastritis E; Dimopoulos MA; Vij R; Bansal D; Dingli D; Nasr SH; Leung N
    Am J Hematol; 2016 Sep; 91(9):E348-52. PubMed ID: 27286661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
    Ri M
    Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma.
    Chan KL; Filshie R; Nandurkar H; Quach H
    Leuk Lymphoma; 2015 Jul; 56(7):2185-6. PubMed ID: 25547654
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-VEGF Cancer Therapy in Nephrology Practice.
    Izzedine H
    Int J Nephrol; 2014; 2014():143426. PubMed ID: 25210627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Syndromes of thrombotic microangiopathy.
    George JN; Nester CM
    N Engl J Med; 2014 Aug; 371(7):654-66. PubMed ID: 25119611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib-induced thrombotic thrombocytopaenic purpura.
    Mehta N; Saxena A; Niesvizky R
    BMJ Case Rep; 2012 Aug; 2012():. PubMed ID: 22854237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma.
    Salmenniemi U; Remes K
    Hematol Rep; 2012 May; 4(2):e13. PubMed ID: 22826795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib.
    Moore H; Romeril K
    Intern Med J; 2011 Apr; 41(4):348-50. PubMed ID: 21507163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma.
    Morita R; Hashino S; Shirai S; Fujita N; Onozawa M; Kahata K; Kondo T; Imamura M; Asaka M
    Int J Hematol; 2008 Sep; 88(2):248-250. PubMed ID: 18636313
    [No Abstract]   [Full Text] [Related]  

  • 38. Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma.
    Field-Smith A; Morgan GJ; Davies FE
    Ther Clin Risk Manag; 2006 Sep; 2(3):271-9. PubMed ID: 18360602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug-induced thrombotic microangiopathy.
    Zakarija A; Bennett C
    Semin Thromb Hemost; 2005 Dec; 31(6):681-90. PubMed ID: 16388419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma.
    George JN; Li X; McMinn JR; Terrell DR; Vesely SK; Selby GB
    Transfusion; 2004 Feb; 44(2):294-304. PubMed ID: 14962323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.